NCT05253859 (CFTR-MAGIC) is a clinical trial of No intervention in Cystic Fibrosis, sponsored by Nottingham University Hospitals NHS Trust.

Who is sponsoring NCT05253859?

NCT05253859 is sponsored by Nottingham University Hospitals NHS Trust.

What drugs are being tested in NCT05253859?

Interventions in NCT05253859: No intervention.

What condition does NCT05253859 study?

NCT05253859 studies Cystic Fibrosis, Gastrointestinal System Disease, Distal Intestinal Obstruction Syndrome, Pancreatic Enzyme Abnormality, Pancreatic Disease, Lung Diseases, Digestive System Disease.

Is NCT05253859 still recruiting?

NCT05253859 is currently completed. Last updated 3 July 2024.

Last reviewed 2024-07-03 · How we verify

NCT05253859: CFTR-MAGIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CFTR Modulators and Gastrointestinal Complications

Completed Last updated 3 July 2024

What this trial tests

trial testing No intervention in Cystic Fibrosis in 47,023 participants. Completed in 10 February 2024.

Timeline

1 October 2021

Primary endpoint
10 February 2024

10 February 2024

Quick facts

Lead sponsor	Nottingham University Hospitals NHS Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	47,023
Start date	1 October 2021
Primary completion	10 February 2024
Estimated completion	10 February 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

No intervention

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →
Gastrointestinal System Disease — all drugs for Gastrointestinal System Disease →
Distal Intestinal Obstruction Syndrome — all drugs for Distal Intestinal Obstruction Syndrome →
Pancreatic Enzyme Abnormality — all drugs for Pancreatic Enzyme Abnormality →

Sponsor

Nottingham University Hospitals NHS Trust

Who can join

Eligibility, any sex, with Cystic Fibrosis or Gastrointestinal System Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To elucidate the similarities and distinctions in non-pulmonary manifestations of cystic fibrosis (CF) including distal intestinal obstruction syndrome (DIOS) incidence and pancreatic enzyme replacement therapy (PERT) use between US and UK CF populations in a parallel study using data from the UK and US CF registries. To assess how CFTR modulators impacted upon recorded PERT use and incidence of DIOS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.
Calthorpe R, Rosenfeld M, Goss CH, Green N, et al · · 2024 · cited 3× · PMID 38342635 · DOI 10.1016/j.jcf.2024.01.011

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Nottingham University Hospitals NHS Trust trials

Trials by the same sponsor.

NCT07350408 — Mapping Post-falls Organisational Processes in Care Homes · recruiting
NCT07036081 — A Single Arm Intervention Study to Assess the Acceptability, Tolerance and Ease of Use of Wilbo's Blends+ (Commercial En · NA · completed
NCT07303569 — Prevention of Pressure Injury (PI) in Hospitalised Infants, Children, and Young People (CYP) (Aged 0-19 Years) · recruiting
NCT06572345 — Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study · NA · recruiting
NCT07136298 — Seizure Identification on the Intensive Care Unit (ICU) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05253859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nottingham University Hospitals NHS Trust
Last refreshed: 3 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05253859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing